Preventing Cognitive Decline and Dementia from Cerebral Small Vessel Disease (LACunar Intervention Trial-1, LACI-1) About 35,000 people each year in the UK have a type of stroke, called ‘lacunar’ or ‘small vessel’ stroke. Some drugs that are commonly used in other vessel diseases may help improve small vessel function and prevent worsening of brain damage. This study is testing two drugs, one has not yet been tested specifically in this disease in the UK (cilostazol), the other is widely used in the UK in heart disease but not stroke (isosorbide mononitrate). The aims of the study are to find out how patients feel taking the drugs, to test if they improve blood vessel function and find out if both drugs might be better than just one, before going on to a large clinical trial to find out if these drugs prevent worsening of small vessel disease. Image Chief Investigator: Professor Joanna M Wardlaw Number and location of participating sites (by region/ country): UK – Edinburgh & Nottingham EudraCT number: 2015‐001953‐33 ISRCTN number: ISRCTN12580546 Funder: Alzheimer’s Society Start end date of grant: 30/09/2015 – 30/09/2017 Recruitment: 16/03/2016 Current status: Recruiting Trial unblinding information: Open label trial - in circumstances where identification of trial drug is necessary please call the 24hr helpline 0131 242 7427. Contact details: Sponsor(s) University of Edinburgh & NHS Lothian – ACCORD: http://accord.scot/ Professor Joanna M Wardlaw Neuroimaging Sciences, University of Edinburgh, Centre for Clinical Brain Sciences (CCBS), Chancellor's Building, 49 Little France Crescent, Edinburgh EH16 4SB Tel: +44 (0)131 465 959; Email: Joanna.Wardlaw@ed.ac.uk Trial Manager: Julia Boyd; Prevent-SVD.trial@ed.ac.uk ECTU Involvement: Trial Management This article was published on 2024-09-24
